Cochrane Review Group

Infectious Diseases

135 systematic reviews in Infectious Diseases ask 1,518 questions. 8.9% have no studies to answer them, 23.1% rest on very low certainty evidence and 30.5% reach moderate or high certainty.

Reviews

135

Questions

1,518

current versions

No studies

8.9%

Moderate or high

30.5%

No studies 135 · 8.9%Ungraded 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Infectious Diseases

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment All‐cause mortality – at 28 to 30 days, or in‐hospital · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.84 [0.49, 1.46]	11 studies · 3459 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Progression to invasive mechanical ventilation · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	RR 0.86 [0.68, 1.09]	8 studies · 1383 participants	Very low
Favipiravir vs no treatment, supportive treatment, or other antiviral treatment Time to clinical improvement (defined as time to a 2‐point reduction in patients’ admission status on WHO’s ordinal scale) · people with confirmed COVID‐19 Favipiravir for treating COVID‐19 (2024) · Cochrane	HR 1.13 [0.69, 1.83]	4 studies · 721 participants	Very low
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
wMel‐Wolbachia infected Aedes aegypti deployments vs no deployments Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection Wolbachia ‐carrying Aedes mosquitoes for preventing dengue infection (2024) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR NRCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Cluster‐RCTs · adults and children Interventions to improve sanitation for preventing diarrhoea (2023) · Cochrane	no estimate extracted	NR	No studies

Reviews 135

Intermittent preventive treatment for malaria in infants

Esu, EB, Oringanje, C, et al. · Cochrane Database of Systematic Reviews · 2021

Infectious Diseases

Thinnest evidence

Reviews 135

Intermittent preventive treatment for malaria in infants

Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults

Piperonyl butoxide (PBO) combined with pyrethroids in insecticide‐treated nets to prevent malaria in Africa

Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis

Ivermectin treatment in humans for reducing malaria transmission

Rapid versus standard antimicrobial susceptibility testing to guide treatment of bloodstream infection

Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19

Screening tests for active pulmonary tuberculosis in children

Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms

Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV

Chemotherapy for second‐stage human African trypanosomiasis: drugs in use

Probiotics for treating acute infectious diarrhoea

Paediatric formulations of artemisinin‐based combination therapies for treating uncomplicated malaria in children

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria

Anthelmintic drugs for treating ascariasis

Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax

Rapid diagnostic tests for Plasmodium vivax malaria in endemic countries

Rapid diagnostic tests for plague

Treating progressive disseminated histoplasmosis in people living with HIV

Hand cleaning with ash for reducing the spread of viral and bacterial infections: a rapid review

Public health deworming programmes for soil‐transmitted helminths in children living in endemic areas

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis

Antiamoebic drugs for treating amoebic colitis

Racecadotril for acute diarrhoea in children

Artemether for severe malaria